指南与共识腹部技术与安全US

国际共识:肠道超声在炎症性肠病临床试验中的应用

International consensus on the use of intestinal ultrasound in inflammatory bowel disease trials.
指南 / 共识 · J Crohns Colitis · 2025-01-01

35名国际胃肠病学家和放射科医生通过改良Delphi流程,就炎症性肠病试验中肠道超声的应答、缓解定义及评估时机达成共识,共150条声明,涵盖一般IBD、腔内克罗恩病、肛周克罗恩病和溃疡性结肠炎四个领域。

要点

  • 腔内克罗恩病和溃疡性结肠炎的超声应答定义为肠壁厚度较基线降低≥25%,或肠壁厚度降低联合彩色多普勒信号至少降低1级等多参数改善。
  • 评估时机:结肠为第4-8周,回肠末端为第12周。
  • 腔内克罗恩病超声缓解定义为肠壁厚度正常化(≤3 mm)或多参数正常化,溃疡性结肠炎类似但乙状结肠正常范围(3-4 mm)尚不确定。

核心结论

  • 该共识提供了标准化的肠道超声定义,以增强炎症性肠病试验的一致性,支持将肠道超声整合到未来研究中。

研究设计与样本

  • 改良Delphi流程国际专家共识,35名国际胃肠病学家和放射科医生参与,共识阈值定义为至少75%同意。

诊断标准与关键数值

  • 腔内克罗恩病和溃疡性结肠炎的超声应答:肠壁厚度较基线降低≥25%,或肠壁厚度降低联合彩色多普勒信号至少降低1级或另一肠道超声参数改善。
  • 评估时机:结肠为第4-8周,回肠末端为第12周。
  • 腔内克罗恩病超声缓解:肠壁厚度正常化(≤3 mm)或多参数(肠壁厚度、彩色多普勒信号及所有其他肠道超声参数)正常化。
  • 溃疡性结肠炎提出类似缓解标准,但乙状结肠肠壁厚度正常范围(3-4 mm)仍不确定。
  • 支持克罗恩病肠道超声评分(BUSS)和溃疡性结肠炎Milan超声标准(MUC)作为试验的标准化评分系统。

临床应用与阅片要点

  • 在炎症性肠病临床试验中采用共识定义的超声应答和缓解标准,以及规定的评估时机。
  • 克罗恩病试验可使用肠道超声评分(BUSS),溃疡性结肠炎试验可使用Milan超声标准(MUC)作为标准化评分系统。

局限性

  • 溃疡性结肠炎乙状结肠肠壁厚度正常范围(3-4 mm)仍不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND AIMS: Intestinal ultrasound (IUS) is increasingly used to monitor treatment efficacy in inflammatory bowel disease (IBD) trials. However, standardized definitions for response, remission, and optimal assessment timing remain undefined. An international expert consensus meeting was held to establish IUS endpoints for clinical trials.

METHODS: A panel of 35 international gastroenterologists and radiologists participated in a modified Delphi process, reviewing the literature and developing consensus statements. Agreement was defined as at least 75% consensus.

RESULTS: Consensus was reached on 150 statements across four domains: general IBD (30 statements), luminal Crohn's disease (CD) (43), perianal CD (51), and ulcerative colitis (UC) (26). For luminal CD and UC, ultrasound response was defined by: (1) a ≥25% reduction in bowel wall thickness (BWT) from baseline, or (2) multifactorial improvement, combining BWT reduction with ≥1 grade decrease in color Doppler signal (CDS) or another IUS parameter. Assessments were set at weeks 4-8 for the colon and week 12 for the terminal ileum. Ultrasound remission in luminal CD was defined as: (1) BWT normalization (≤3 mm) or (2) normalization of multiple parameters, including BWT, CDS, and all other IUS parameters. Similar remission criteria were proposed for UC, but the sigmoid BWT normal range (3-4 mm) remained uncertain. The bowel ultrasound score (BUSS) for CD and the Milan ultrasound criteria (MUC) for UC were supported as standardized scoring systems for trials.

CONCLUSION: This consensus provides standardized IUS definitions to enhance consistency in IBD trials, supporting the integration of IUS in future research.

来源:J Crohns Colitis,查看原文。版权归原作者所有。

引用

  1. Allocca M, Jairath V, Sands BE, et al. International consensus on the use of intestinal ultrasound in inflammatory bowel disease trials. J Crohns Colitis. 2025. PMID: 40973472. doi:10.1093/ecco-jcc/jjaf170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。